Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 5/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 4/20 | 0.31 |
| ▸ | JAK1 | P23458 | 4/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22157134 | 1.00 | CDK2 (0.38) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL22123884 | 0.94 | CDK2 (0.39) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL30171959 | 0.94 | CDK2 (0.39) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL22122846 | 0.93 | CDK2 (0.38) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL30172018 | 0.93 | CDK2 (0.38) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL22124715 | 0.91 | CDK2 (0.34) | CDK2CDK1PTK6TTKJAK2 | |
| SCHEMBL30171828 | 0.91 | CDK2 (0.34) | CDK2CDK1PTK6TTKJAK2 | |
| SCHEMBL30385985 | 0.90 | CDK2 (0.37) | CDK2CDK1LMNAPTK6TTK | |
| SCHEMBL22124697 | 0.90 | CDK2 (0.34) | CDK2CDK1PTK6TTKJAK2 | |
| SCHEMBL25445314 | 0.88 | MAPKAPK5 (0.35) | CDK2CDK1PTK6TTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | CDK2 1010/4885CDK1 615/4885LMNA 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.